TYPE II ANTI-CD20 ANTIBODIES FOR REDUCING FORMATION OF ANTI-DRUG ANTIBODIES

• Main Authors: EVA ROSSMANN, CHRISTIAN KLEIN, JOSE SARO, STEFAN EVERS, MARINA BACAC, PAVEL PISA, PABLO UMANA
• Format: Patent
• Language: English; Japanese
• Published: 14.10.2021
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

To provide Type II anti-CD20 antibodies for use in methods of treating diseases and methods for reducing formation of anti-drug antibodies in response to the administration of a therapeutic agent using the antibodies.SOLUTION: Disclosed is a Type II anti-CD20 antibody for use in a method of treating a disease in a subject, the method comprising a treatment regimen comprising: (i) administering the Type II anti-CD20 antibody to the subject, and after a certain period of time, (ii) administering a therapeutic agent to the subject, where the period of time between the administration of the Type II anti-CD20 antibody and the administration of the therapeutic agent is sufficient for reducing the number of B-cells in the subject in response to the administration of the Type II anti-CD20 antibody, where the Type II anti-CD20 antibody is an IgG1 antibody, and at least about 40% of the N-linked oligosaccharides in the Fc region of the anti-CD20 antibody are non-fucosylated. Also disclosed is a method for reducing the formation of anti-drug antibodies in response to the administration of a therapeutic agent using the Type II anti-CD20 antibody.SELECTED DRAWING: None 【課題】疾患を治療する方法に使用するＩＩ型抗ＣＤ２０抗体、及び該抗体を使用した治療剤の投与に応答した抗薬物抗体の形成を減少させる方法を提供する。【解決手段】（ｉ）ＩＩ型抗ＣＤ２０抗体の対象への投与、及び、一定期間後に連続して（ｉｉ）治療剤の対象への投与を含む治療レジメンを含み、ＩＩ型抗ＣＤ２０抗体の投与と治療剤の投与との間の期間はＩＩ型抗ＣＤ２０抗体の投与に応答した対象におけるＢ細胞の数を減少させるために十分であるＩＩ型抗ＣＤ２０抗体であって、該抗体がＩｇＧ１抗体、かつ、抗ＣＤ２０抗体のＦｃ領域におけるＮ−結合型オリゴ糖の少なくとも約４０％が非フコシル化されているＩＩ型抗ＣＤ２０抗体、及び該ＩＩ型抗ＣＤ２０抗体を使用した治療剤の投与に応答した抗薬物抗体の形成を減少させる方法を提供する。【選択図】なし